Brief: Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis Therapeutics

Esperion Therapeutics

02/04/2026 22:37

April 2 (Reuters) - Esperion Therapeutics Inc ESPR.O:

ATHYRIUM CAPITAL MANAGEMENT AND ESPERION ENTER INTO $50 MILLION JAPAN ROYALTY FINANCING TO SUPPORT STRATEGIC ACQUISITION OF CORSTASIS THERAPEUTICS

ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO RECEIVE TIERED ROYALTIES OF 12%-33% AND MILESTONE PAYMENTS UNTIL 2.0X INVESTMENT

ESPERION THERAPEUTICS INC - FINANCING SUPPORTS ESPERION'S ACQUISITION OF CORSTASIS THERAPEUTICS, DEVELOPER OF ENBUMYST

ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO BUY 100% OF ESPERION'S ROYALTY INTEREST ON OTSUKA'S JAPAN SALES FROM JAN 1, 2026

Source text: ID:nGNX4sqmz8

Further company coverage: ESPR.O

 ((Reuters.Briefs@thomsonreuters.com;))